Celldex Therapeutics, Inc. Forecast, price target & analysts
Celldex Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Celldex Therapeutics, Inc. Classifications & Recommendation:
Celldex Therapeutics, Inc. Price Target
| Target Price | $54.06 |
| Price | $24.37 |
| Potential |
121.83%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target Celldex Therapeutics, Inc. 2026 .
The average Celldex Therapeutics, Inc. target price is $54.06.
This is
121.83%
register free of charge
$94.50
287.77%
register free of charge
$25.25
3.61%
register free of charge
|
|
| A rating was issued by 22 analysts: 18 Analysts recommend Celldex Therapeutics, Inc. to buy, 3 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Celldex Therapeutics, Inc. stock has an average upside potential 2026 of
121.83%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 7.02 | 3.40 |
| 2.03% | 51.58% | |
| EBITDA Margin | -2,733.62% | -7,548.26% |
| 35.28% | 176.13% | |
| Net Margin | -2,248.72% | -6,941.26% |
| 9.39% | 208.68% |
16 Analysts have issued a sales forecast Celldex Therapeutics, Inc. 2025 . The average Celldex Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Celldex Therapeutics, Inc. EBITDA forecast 2025. The average Celldex Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
17 Celldex Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Celldex Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.45 | -3.55 |
| 16.10% | 44.90% | |
| P/E | negative | |
| EV/Sales | 290.98 |
17 Analysts have issued a Celldex Therapeutics, Inc. forecast for earnings per share. The average Celldex Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Celldex Therapeutics, Inc....
Current Celldex Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Mizuho |
Locked
➜
Locked
|
Locked | Oct 21 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Oct 13 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Sep 17 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 20 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Aug 20 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 20 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 20 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Mizuho:
Locked
➜
Locked
|
Oct 21 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Oct 13 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Sep 17 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 20 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Aug 20 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 20 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 20 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
